Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)2448-2453
Number of pages6
JournalTranslational Cancer Research
Volume12
Issue number10
DOIs
StatePublished - 2023

Keywords

  • Metastatic castration-resistant prostate cancer (mCRPC)
  • homologous repair deficiency (HRD)
  • poly-ADP ribose polymerase inhibitors (PARPi)
  • rucaparib

PubMed: MeSH publication types

  • Editorial
  • Comment

Cite this